Hepatitis C Virus Infection Suppresses the Interferon Response in the Liver of the Human Hepatocyte Chimeric Mouse
暂无分享,去创建一个
T. Tsunoda | M. Imamura | N. Hiraga | K. Chayama | D. Miki | F. Miya | T. Kohno | H. Ochi | Yizhou Zhang | M. Tsuge | Shoichi Takahashi | H. Abe | Y. Fujimoto | Mayu Ohnishi | C. N. Hayes | Shoichi Takahashi | Tomohiko Kohno
[1] B. Bay,et al. Modulation of metallothionein isoforms is associated with collagen deposition in proliferating keloid fibroblasts in vitro , 2010, Experimental dermatology.
[2] M. Imamura,et al. Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy , 2010, Antiviral therapy.
[3] K. Horimoto,et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. , 2010, Gastroenterology.
[4] A. Koike,et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C , 2009, Nature Genetics.
[5] Jacques Fellay,et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance , 2009, Nature.
[6] F. Tacke,et al. Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. , 2009, Gastroenterology.
[7] M. Daveau,et al. Novel serum markers of fibrosis progression for the follow-up of hepatitis C virus-infected patients. , 2009, The American journal of pathology.
[8] Yoshiyuki Suzuki,et al. Poor Response to Pegylated Interferon and Ribavirin in Older Women Infected with Hepatitis C Virus of Genotype 1b in High Viral Loads , 2009, Digestive Diseases and Sciences.
[9] M. Katze,et al. HCV Induces Oxidative and ER Stress, and Sensitizes Infected Cells to Apoptosis in SCID/Alb-uPA Mice , 2009, PLoS pathogens.
[10] P. Bioulac-Sage,et al. Transient and etiology-related transcription regulation in cirrhosis prior to hepatocellular carcinoma occurrence. , 2009, World journal of gastroenterology.
[11] M. Imamura,et al. Establishment of an infectious genotype 1b hepatitis C virus clone in human hepatocyte chimeric mice. , 2008, The Journal of general virology.
[12] Edward J Oakeley,et al. Interferon signaling and treatment outcome in chronic hepatitis C , 2008, Proceedings of the National Academy of Sciences.
[13] K. Koike,et al. PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. , 2008, The Journal of clinical investigation.
[14] M. Cam,et al. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response , 2007, Hepatology.
[15] Yoshiyuki Suzuki,et al. Prediction of Response to Pegylated Interferon and Ribavirin in Hepatitis C by Polymorphisms in the Viral Core Protein and Very Early Dynamics of Viremia , 2007, Intervirology.
[16] S. Akira,et al. Hepatitis C Virus Nonstructural Protein 5A Modulates the Toll-Like Receptor-MyD88-Dependent Signaling Pathway in Macrophage Cell Lines , 2007, Journal of Virology.
[17] M. Imamura,et al. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon , 2007, FEBS letters.
[18] M. Imamura,et al. Dual effect of APOBEC3G on Hepatitis B virus. , 2007, The Journal of general virology.
[19] Keiji Tanaka,et al. Critical role of PA28γ in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis , 2007, Proceedings of the National Academy of Sciences.
[20] M. Honda,et al. Different signaling pathways in the livers of patients with chronic hepatitis B or chronic hepatitis C , 2006, Hepatology.
[21] K. Shimotohno,et al. High expression of APOBEC3G in patients infected with hepatitis C virus , 2006, Journal of Molecular Histology.
[22] H. Conjeevaram,et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. , 2006, Gastroenterology.
[23] M. Katze,et al. Host-Specific Response to HCV Infection in the Chimeric SCID-beige/Alb-uPA Mouse Model: Role of the Innate Antiviral Immune Response , 2006, PLoS pathogens.
[24] S. Wain-Hobson,et al. Interferon‐inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication , 2006, Hepatology.
[25] Deborah Chavez,et al. Genomic response to interferon‐α in chimpanzees: Implications of rapid downregulation for hepatitis C kinetics , 2006, Hepatology.
[26] R. Bartenschlager,et al. E2 of Hepatitis C Virus Inhibits Apoptosis1 , 2005, The Journal of Immunology.
[27] Zhijian J. Chen,et al. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[28] T. Asselah,et al. Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. , 2005, Gastroenterology.
[29] M. Imamura,et al. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus , 2005, Hepatology.
[30] Osamu Takeuchi,et al. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction , 2005, Nature Immunology.
[31] Z. Zhai,et al. VISA Is an Adapter Protein Required for Virus-Triggered IFN-β Signaling , 2005 .
[32] Zhijian J. Chen,et al. Identification and Characterization of MAVS, a Mitochondrial Antiviral Signaling Protein that Activates NF-κB and IRF3 , 2005, Cell.
[33] M. Malim,et al. APOBEC‐mediated interference with hepadnavirus production , 2005, Hepatology.
[34] Yoshiyuki Suzuki,et al. Association of Amino Acid Substitution Pattern in Core Protein of Hepatitis C Virus Genotype 1b High Viral Load and Non-Virological Response to Interferon-Ribavirin Combination Therapy , 2005, Intervirology.
[35] M. Imamura,et al. G to A hypermutation of hepatitis B virus , 2005, Hepatology.
[36] T. Asahara,et al. Near completely humanized liver in mice shows human-type metabolic responses to drugs. , 2004, The American journal of pathology.
[37] M. Malim,et al. APOBEC-Mediated Editing of Viral RNA , 2004, Science.
[38] G. Ippolito,et al. HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin. , 2004, Journal of hepatology.
[39] Michel Henry,et al. APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. , 2004, Nucleic acids research.
[40] Keiji Tanaka,et al. Proteasome Activator PA28γ-Dependent Nuclear Retention and Degradation of Hepatitis C Virus Core Protein , 2003, Journal of Virology.
[41] R. König,et al. Species-Specific Exclusion of APOBEC3G from HIV-1 Virions by Vif , 2003, Cell.
[42] Gersende Caron,et al. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts , 2003, Nature.
[43] Hui Zhang,et al. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA , 2003, Nature.
[44] J. Hoofnagle,et al. Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin , 2003, Hepatology.
[45] F. Clavel,et al. Hypermutation of HIV-1 DNA in the Absence of the Vif Protein , 2003, Science.
[46] Rafael A Irizarry,et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.
[47] Terence P. Speed,et al. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..
[48] M. Grace,et al. Interferon‐α as an immunotherapeutic protein , 2002, Journal of Leukocyte Biology.
[49] C. Samuel,et al. Antiviral Actions of Interferons , 2001, Clinical Microbiology Reviews.
[50] Kenneth Koury,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[51] D. Tyrrell,et al. Hepatitis C virus replication in mice with chimeric human livers , 2001, Nature Medicine.
[52] K. Koike,et al. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. , 2001, Cancer research.
[53] L. Platanias,et al. Signaling pathways activated by interferons. , 1999, Experimental hematology.
[54] P Parham,et al. Analysis of a successful immune response against hepatitis C virus. , 1999, Immunity.
[55] Yoshiharu Matsuura,et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice , 1998, Nature Medicine.
[56] M J Clemens,et al. The double-stranded RNA-dependent protein kinase PKR: structure and function. , 1997, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[57] K Koike,et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. , 1997, The Journal of general virology.
[58] N Enomoto,et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. , 1996, The New England journal of medicine.
[59] R. Silverman,et al. 2-5A-dependent RNase Molecules Dimerize during Activation by 2-5A (*) , 1995, The Journal of Biological Chemistry.
[60] P. Staeheli,et al. Mx proteins: GTPases with antiviral activity. , 1993, Trends in cell biology.
[61] R. Purcell,et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. , 1989, The New England journal of medicine.
[62] 平賀 伸彦. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon , 2008 .
[63] Z. Zhai,et al. VISA is an adapter protein required for virus-triggered IFN-beta signaling. , 2005, Molecular cell.
[64] Zhijian J. Chen,et al. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. , 2005, Cell.
[65] Keiji Tanaka,et al. Proteasome activator PA28gamma-dependent nuclear retention and degradation of hepatitis C virus core protein. , 2003, Journal of virology.
[66] Y. Jeong,et al. Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection , 2003 .
[67] M. Grace,et al. Interferon-alpha as an immunotherapeutic protein. , 2002, Journal of leukocyte biology.